Market
What stage will Tubulis's ADC candidate reach by end of 2025?
2
Resolution / Starting Odds
Preclinical • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 or beyond • 25%
Clinical trial registries or public announcements from Tubulis
Story
Gilead and Tubulis Sign $20M ADC Agreement for Solid Tumors with $30M Opt-in Fee and $415M Milestones
Dec 3, 2024, 12:54 PM
Gilead Sciences Inc. has entered into an exclusive option and license agreement with Tubulis to develop an antibody-drug conjugate (ADC) candidate targeting select solid tumors. The agreement includes an upfront payment of $20 million, a $30 million opt-in fee, and potential milestone payments totaling up to $415 million, along with mid-single to low double-digit tiered royalties. The specific target of the ADC has not been disclosed, but it is indicated that it will be a Topoisomerase I (TopoI) ADC.
View original story
Similar markets
Less than 10% • 25%
20-30% • 25%
10-20% • 25%
More than 30% • 25%
Neutral results requiring further study • 25%
Negative results halting development • 25%
Other outcome • 25%
Positive results leading to Phase 2 • 25%
FDA Fast Track designation • 25%
None of the above • 25%
Positive Phase 1 results • 25%
Phase 2 initiation • 25%
Pfizer • 25%
Roche • 25%
AstraZeneca/Daiichi Sankyo • 25%
Other • 25%
Inconclusive results • 25%
Trial extended • 25%
Negative results • 25%
Positive results • 25%
Drug C • 25%
Drug A • 25%
Drug B • 25%
None • 25%
Phase 3 completion • 25%
Phase 2 completion • 25%
No significant milestone • 25%
Phase 1 completion • 25%
Moderate improvement • 25%
Worse outcomes • 25%
Significant improvement • 25%
No improvement • 25%